Zimmer Biomet has cemented a multiyear partnership with Biocomposites to exclusively distribute its Genex bone graft substitute in the U.S.
Genex is a biphasic composite designed to balance osteoconductive scaffold strength and allow for optimal remodeling of bone in the body, the devicemaker said in a March 22 news release.
The product was recently upgraded with a new closed-mixing system to shorten prep time and extend working time. It also includes a wider portfolio of delivery options to help surgeons inject, mold or prepare beads in line with their chosen technique.
Genex is used in more than 15,000 procedures a year in more than 30 countries, according to Biocomposites CEO Michael Harris, who said "the upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the U.S."
Biocomposites products are designed to regenerate bone and target infection risks in various specialties, including spine, orthopedics, trauma, foot and ankle and musculoskeletal infection, the release said.